The Indian Biotech Company, Biocon to colloborate with Nobex Corporation of United States to develop a new oral peptide drug for cardiovascular diseases.
The Indian Biotech Company, Biocon to colloborate with Nobex Corporation of United States to develop a new oral peptide drug for cardiovascular diseases. The spokesperson of Biocon informed that the company has gone into global research collaboration on Tuesday for development of peptide based product for treatment of cardiovasculoar diseases. The Biocon press release said, “The collaboration combines the peptide production capabilities of Biocon with the proprietary oral peptide deliver technology of Nobex. Biocon and Nobex plan to advance the oral human brain type natriuretic peptide (hBNP) program towards an Investigational New drug filing with the US food and Drug Administration in 2007 and clinical trials beginning later that year.
“Administration of hBNP by continuous infusion was approved by the FDA in August 200 for the treatment of acute congestive heart failure in the hospital care setting. The intent of an oral hBNP would be to have a product available for chronic use, rather than only for acute use for a number of potential indications, including early stage heart failure patients.’ It said.“By co-developing a therapeutic product such a oral hBNP of substantial clinical and market value in treating heart failure and other potential cardiovascular indications, we are taking another step towards our innovative product development strategy,” the release quoted Ms Kiran Mazumdar-Shaw, chairman and managing director of Biocon, as saying.
